Pathogenesis of Seborrheic Dermatitis
Seborrheic dermatitis is a common, chronic, relapsing inflammatory skin condition that primarily affects sebum-rich areas of the body. While the exact etiology remains complex, current scientific consensus links its pathogenesis to three main factors: sebum production, colonization by Malassezia yeast, and the host’s individual immune response. Sebaceous glands secrete lipids (sebum) that act as a nutrient source for Malassezia (specifically Malassezia restricta and Malassezia globosa), which are commensal yeasts on human skin. These yeasts produce lipases that break down sebum triglycerides into free fatty acids, such as oleic acid. In susceptible individuals, these unsaturated fatty acids penetrate the stratum corneum, causing skin barrier irritation and triggering an inflammatory cytokine response. This process leads to accelerated epidermal turnover and abnormal desquamation, presenting as scaling and redness.
Clinical Presentation, Common Sites, and Differentials
Seborrheic dermatitis presents as erythematous plaques covered with greasy, yellowish, or white scales, often accompanied by mild-to-moderate pruritus. The distribution corresponds to areas of high sebaceous gland density:
- Scalp: The most frequent site, ranging from mild scaling (dandruff, or pityriasis capitis) to thick, adherent, greasy crusts. In infants, this presentation is referred to as “cradle cap.”
- Face: Commonly affects the eyebrows, glabella (area between the eyebrows), nasolabial folds, retroauricular areas (behind the ears), and the eyelids (where it can cause seborrheic blepharitis, presenting as crusting and irritation along the eyelash line).
- Trunk: May present as petaloid or annular plaques on the chest (presternal area) or upper back.
Clinicians must differentiate seborrheic dermatitis from psoriasis (which presents with thicker, silvery scales and the Auspitz sign, on the extensor surfaces) and atopic dermatitis, which is typically found on flexural surfaces and is associated with more intense xerosis and personal history of atopy.
Over-the-Counter and Prescription Antifungal Shampoos
For scalp involvement, medicated shampoos are the first-line therapy, designed to reduce Malassezia populations and control inflammation. Active ingredients include:
- Ketoconazole (1% OTC, 2% Prescription): An imidazole antifungal that inhibits fungal cell membrane synthesis by blocking ergosterol synthesis. It is highly effective and possesses intrinsic anti-inflammatory properties.
- Selenium Sulfide (2.5%): An antifungal and cytostatic agent that reduces epidermal cell turn-over.
- Zinc Pyrithione (1%): A widely used OTC agent with both antifungal and antibacterial properties.
- Ciclopirox (1%): A hydroxypiridone antifungal that disrupts active transport and cell membrane integrity in fungal cells.
- Coal Tar and Salicylic Acid: These keratolytic agents act by softening and facilitating the removal of thick, adherent scales from the scalp.
Rotation of shampoos is often clinically recommended to prevent tachyphylaxis (where the scalp becomes resistant or less responsive to a single active ingredient over time). For example, rotating between an azole-based shampoo (ketoconazole) and a selenium sulfide or zinc pyrithione shampoo can optimize control.
💡 💡 Medicated Shampoo Contact Time
A common cause of treatment failure in seborrheic dermatitis is inadequate contact time. Advise patients to apply the medicated shampoo directly to the wet scalp, massage it thoroughly into the skin, and leave it in place for 5 to 10 minutes before rinsing. This allows the active antifungal ingredients to penetrate the stratum corneum and hair follicles.
Facial and Body Skincare Recommendations
Managing facial seborrheic dermatitis requires a gentle approach, as facial skin is highly sensitive. During active flares, a twice-weekly wash with a ketoconazole or zinc pyrithione shampoo can be used as a face wash. Topical anti-inflammatory agents, such as low-potency corticosteroids (e.g., hydrocortisone 1% cream) or topical calcineurin inhibitors (e.g., tacrolimus 0.03% ointment or pimecrolimus 1% cream), are highly effective for reducing facial redness and scaling, but topical steroids should be limited to short-term use (under 2 weeks) to prevent steroid-induced rosacea or skin atrophy. Daily skincare should include soap-free, pH-balanced cleansers and lightweight, non-comedogenic moisturizers. Patients should avoid heavy, greasy oils (like olive oil), which can feed Malassezia yeast and worsen the condition. When managing patients with overlapping conditions such as eczema (atopic dermatitis) or acne vulgaris, therapies must be selected carefully to prevent irritation of the skin barrier.
💡 Frequently Asked Questions (FAQ)
Q1: Is seborrheic dermatitis contagious?
A1: No, seborrheic dermatitis is not contagious. It is driven by Malassezia yeast, which is a normal, non-infectious part of the human skin microbiome. The disease occurs due to an individual’s unique inflammatory reaction to the metabolic byproducts of this yeast, rather than an infection that can be spread to others.
Q2: Can seborrheic dermatitis cause permanent hair loss?
A2: Seborrheic dermatitis does not cause permanent hair loss. However, severe scalp inflammation, combined with vigorous scratching due to intense itching, can lead to temporary hair shedding (telogen effluvium) or damage to hair shafts. Hair typically regrows fully once the scalp inflammation is controlled.
Q3: Why does seborrheic dermatitis flare up during winter or periods of high stress?
A3: Cold, dry winter weather reduces skin barrier moisture, making the skin more susceptible to irritation. Psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, releasing cortisol and neuropeptides that can alter sebum composition and impair the skin’s immune response, triggering flares.
📚 References & Sources
- Borda, L. J., & Wikramanayake, T. C. (2015). Seborrheic Dermatitis and Dandruff: A Comprehensive Review. Journal of Clinical and Investigative Dermatology, 3(2), 10.13188/2373-1044.1000019.
- Kastarinen, H., et al. (2014). Topical anti-inflammatory agents for seborrheic dermatitis of the face and scalp. Cochrane Database of Systematic Reviews, (5), CD009446.